Table 2 Clinical trials using γδ T cell based cancer immunotherapies
From: Gamma-delta (γδ) T cells: friend or foe in cancer development?
Cell types | Diseases | Cell sources | Number of patients | Phase of clinical trail | Outcome | References | ||
|---|---|---|---|---|---|---|---|---|
Response (n) | RR (%) | CBR (%) | ||||||
Vγ9 Vδ2 T | Prostate cancer | PBMC | 18 | I | SD:5; PR:3; PD:3; NE:7 | 27 | 73 | Dieli et al. [50] |
γδ T | NSCLC | PBMC | 10 | I | SD:3; PD:5; NE:2 | 0 | 38 | Nakajima et al. [91] |
Vγ9 Vδ2 T | NSCLC | PBMC | 15 | I | SD:6; PD:6; NE:3 | 0 | 50 | Sakamoto et al. [92] |
LAK:αβT, γδT, NK | Breast cancer | PBMC | 20 | I | PR:3; SD:1; PD:6; NE:10 | 30 | 40 | Noguchi et al. [93] |
Vγ9 Vδ2 T | Lung cancer, stomach cancer, others | PBMC | 5 | I | PD:2; SD:2; NE:1 | 0 | 50 | Noguchi et al. [93] |
Vγ9 Vδ2 T | RCC | PBMC | 12 | I | SD:7; PD:1; NE:4 | 0 | 88 | Lang et al. [94] |
γδ T | RCC | PBMC | 11 | I/II | CR:1; SD:5; PD:5 | 9 | 55 | Kobayashi et al. [95] |
Vγ9Vδ2 T | CRC | PBMC | 6 | I | CR:1; PR:4; NE:1 | 100 | 100 | Izumi et al. [96] |
γδ T | NSCLC | PBMC | 15 | I | SD:6; PD:6; NE:3 | 0 | 50 | Kakimi et al. [97] |
Vγ9Vδ2 T | RCC | In vivo expansion | 10 | I | PR:1; SD:6; NE:3 | 14 | 100 | Bennouna et al. [98] |
LAK:αβT, γδT, NK | RCC, MM, AML | In vivo expansion | 21 | I/II | CR:6; PR:2; PD:12; NE:1 | 40 | 40 | Kunzmann et al. [103] |
LAK:αβT, γδT, NK | Advanced hematological malignancies | In vivo expansion | 4 | I | CR:3; PD:1 | 75 | 75 | Wilhelm et al. [99] |
Total | 147 | SD:41; CR:11; PR:13; PD:47; NE:33 | 21 | 57 | ||||